4DMedical Ltd (ASX: 4DX) shares were one of the fastest-growing on the planet in 2025. The healthcare technology company, which is focused on advanced respiratory imaging and ventilation analysis for the treatment of lung and respiratory diseases, saw its share price explode last year after its flagship product rocketed to success following successful partnerships and commercial contracts.
A good run of financial results and increased adoption of its technology, all while the company smashed its milestone goals throughout the year, sent the share price rocketing.
Most recently, 4DMedical announced that UC San Diego Health was the latest institution to adopt its flagship CT:VQ product. There has already been uptake by other centres, including Stanford University, the Cleveland Clinic, and the University of Miami.
Image source: Getty Images
Where is the 4DMedical share price now?
At the time of writing, the shares are 0.92% lower at $3.76 each. The drop means the shares are now 16.96% lower year to date and have fallen 26.18% from their all-time high of $5.09 in mid-January.
But it isn't all bad news. Since starting their speedy ascent in August last year, 4DMedical shares have rocketed 1,109.68% and they're now 583.64% above where they were just 12 months ago.
The question now is, what's next? Can the share price climb even higher, or is it time to sell up ahead of the next downturn?
Are 4DMedical shares a buy, hold, or sell this year?
Despite the strong rally over the past year and the sell-off this month, analysts remain very bullish on the stock's outlook.
Data shows that two out of three analysts have a strong buy rating on the shares, and the maximum target price is $4.50. That implies a potential 19.68% upside ahead for investors, at the time of writing.
What's next from 4DMedical?
Late last month, the healthcare tech company posted its quarterly update and new commercial development. The announcement revealed that its CT:VQ product has moved beyond regulatory approval and into full commercial execution. The technology has now been adopted in five top-tier US academic centres within five months of FDA clearance.
At the same time, the company also revealed that its SaaS revenue grew 31% in the first half of FY26 and that its net operating cash outflows declined 21% in Q2 FY26.
4DMedical ended the quarter with $56.8 million in cash, rising to a pro forma balance of $206.2 million following a $150 million institutional placement completed in January.
Management estimates the company has around 5.8 quarters of funding available, providing ample time to execute its US commercial strategy.
In 2026, 4DMedical will focus on accelerating the rollout of its newly FDA-approved CT:VQ imaging product through strategic partnerships and new contracts.
